P388 Syngeneic Model Service for Lymphoma

The P388 syngeneic model is the historic lymphoid neoplasm platform of the National Cancer Institute's drug discovery program, engrafting a methylcholanthrene-induced murine lymphoma/leukemia line into immunocompetent DBA/2 hosts to deliver the most standardized survival-based efficacy readouts in oncology. Alfa Cytology delivers this legacy model as a complete preclinical service — authenticated cell banking from NCI-provenance sources, systemic intraperitoneal or solid subcutaneous formats, hybrid-host testing configurations, resistance-sublime arms, and full statistical analysis under the classical %T/C conventions — giving sponsors the most benchmarked lymphoma system in existence.

Overview of P388 Syngeneic Model for Lymphoma

P388 is a foundation stone of modern cancer pharmacology. Chemically induced in the 1950s by skin painting of DBA/2 mice with 3-methylcholanthrene, the line was adopted by the NCI as a primary in vivo screening tool and became the reference tumor against which generations of anticancer compounds were first judged — with activity conventions (%T/C above 125% in early protocols, ILS_max above 30% in later ones, 5-fluorouracil as the standard positive control) that still structure natural-product and medicinal-chemistry papers today. Biologically, P388 is a lymphoid neoplasm of pre-B-cell lineage — classified in the NCIt thesaurus as mouse lymphoma — growing in suspension with surface immunoglobulins and B-cell antigens, a doubling time near 24 hours, and celebrated sensitivity to chemotherapy. Its classical deployment is intraperitoneal: weekly serial passage in DBA/2 mice at 10⁶ cells per animal, with testing conducted in the sturdier hybrid hosts (B6D2F1 or CD2F1) that the screening program favored. Skipper-era kinetic mapping documented the model's rhythm precisely — median survival of 10.3 days by the intraperitoneal route, 13.0 subcutaneously, 8.0 intravenously or intracerebrally, with tumor doubling times of 0.44–0.68 days — and a celebrated BrdU-labeling study revealed its dissemination secret: intraperitoneally inoculated cells implant selectively into the omental "milky spots," the peritoneum's resident immune organelles, at ratios exceeding a thousand to one.

Fig 1. Morphology of the P388D1(IL-1) macrophage-like subline of the P388 syngeneic lymphoma model. (Koren, Hillel S., et al., 1975)

Two extensions give the platform its modern utility. The first is the solid, "lymphoma-like" format: when P388 cells are inoculated subcutaneously they form solid tumors that can be maintained indefinitely by serial fragment transplantation every two weeks — a flank-tumor geometry that supports caliper monitoring, combination regimens, and immunotherapy arms that the ascitic format cannot. The second is the resistance subline collection — P388/ADR selected against doxorubicin, P388/NVB-0.63 and P388/NVB-2.5 against vinorelbine — which powered the classic vinflunine comparative studies and remains a standard substrate for multidrug-resistance and P-glycoprotein research. The family even contributed to immunology itself: P388D1, the macrophage-like ascitic derivative that expresses Fc and complement receptors, phagocytoses latex beads, and secretes IL-1 upon LPS stimulation, became one of the first model macrophage lines for antigen-presentation studies — and modern P388D1-luc derivatives allow longitudinal IVIS tracking of bone-marrow, spleen, and liver infiltration by intravenous administration. Luciferase-tagged P388 variants similarly enable whole-body dissemination mapping on IVIS-class imagers, detecting minimal disease weeks before clinical signs. For sponsors, the P388 platform offers something no other lymphoma model can: absolute benchmarking — seventy years of published comparators behind every survival curve.

Cell Line Information: P388

P388 (ATCC CCL-46; Cellosaurus CVCL_7222; CLS 305226; JCRB0017; RIKEN RCB2776; NCI-DCTD reference stock) is the methylcholanthrene-induced murine lymphoid neoplasm line of DBA/2 origin, classified in the NCIt thesaurus as mouse lymphoma. Resistance-selected and macrophage-like derivatives extend the platform across pharmacology and immunology applications. Core characteristics are compiled below.

Our Services

Engaging Alfa Cytology for the P388 syngeneic model places the NCI's benchmark lymphoma workflow under one accountable team: authenticated, NCI-provenance cell banks are maintained with the line's suspension-culture discipline, DBA/2 propagation colonies and hybrid testing hosts (B6D2F1/CD2F1) are sourced and acclimated, systemic intraperitoneal or solid subcutaneous formats are established at the classical 10⁶-cell inoculum, and treatment arms — including resistance-sublime comparators and combination regimens — are executed through daily mortality monitoring, %T/C and ILS statistics under the historical conventions, and terminal peritoneal-organ histopathology, all under IACUC-compliant conditions and returned as an audit-ready data package.

Workflow of P388 Syngeneic Model Construction

P388 studies follow the classical NCI screening geometry — systemic intraperitoneal or solid subcutaneous — with survival as the definitive endpoint. A standard program proceeds as follows.

1. Cell preparation and quality control: P388 cells (or engineered derivatives) are expanded in suspension at low passage, confirmed mycoplasma-free, and viability verified by trypan blue exclusion; inocula are standardized at 10⁶ viable cells in a defined volume.
2. Host selection and acclimation. DBA/2 mice for propagation (6-week-old females classically) or hybrid hosts: B6D2F1 or CD2F1 — for testing cohorts, all quarantined and acclimated in a specific-pathogen-free barrier facility.
3. Implantation: systemic intraperitoneal route. 10⁶ cells are injected intraperitoneally; for the classical serial-passage workflow, ascitic fluid is harvested aseptically at the passage interval and cell density standardized for the next transfer.
4. Implantation: solid subcutaneous route. 10⁶ cells (or serially passaged tumor-fragment brei for the "lymphoma-like" format) are established in the flank; solid tumors are maintained by fragment transplantation every 2 weeks where continuous passage is required.
5. Randomization and treatment: Mice are randomized into treatment arms, and test articles are administered on protocol schedules — classically daily for five consecutive days (QD1-5) in NCI convention — with 5-fluorouracil as the standard positive control where benchmarking is required.
6. Daily monitoring and survival recording. Mice are monitored daily for mortality, body weight, and clinical signs: classically for 45 days in P388 protocols — with survival times recorded for every animal against predefined humane endpoints.
7. Endpoint analysis under historical conventions: Efficacy is calculated as %T/C (median survival of treated over control × 100; >125% significant in early protocols) or ILS_max (>30% activity threshold); Kaplan–Meier analysis with log-rank testing supports modern reporting.
8. Terminal histopathology and dissemination mapping: Peritoneal organs, omentum, spleen, liver, and bone marrow are examined; luciferase-tagged cohorts undergo terminal ex vivo organ bioluminescence to map dissemination, and tissues undergo H&E with CD45R/B220 and lymphoid-marker immunohistochemistry, with all data consolidated into the final report.

Fig 2. P388 Syngeneic Model construction workflow.

Case Study-P388 Syngeneic Model Development

Alfa Cytology has applied the P388 syngeneic platform to preclinical programs spanning natural-product and medicinal-chemistry screening, multidrug-resistance evaluation using P388/ADR and P388/NVB sublines, combination regimen assessment in the solid lymphoma-like format, and dissemination-biology studies of the intraperitoneal systemic format. In these engagements, daily survival monitoring under the classical %T/C conventions served as the primary endpoint, supplemented by caliper readouts in solid-format arms and terminal peritoneal-organ histopathology with lymphoid-marker panels. Study parameters — host selection, format, inoculum, and endpoint conventions — are tailored to each program. Case materials can be shared under confidentiality agreements upon request.

Why Choose Alfa Cytology?

P388 rewards teams that honor its conventions: the 10⁶-cell inoculum, the hybrid-host logic, the %T/C arithmetic, the 45-day monitoring window — seventy years of comparators expose any deviation instantly. Alfa Cytology fields the classical screening discipline, resistance-sublime expertise, and modern imaging overlay together, making the P388 syngeneic model a dependable backbone for your lymphoma program.

• NCI-provenance banking (ATCC CCL-46 lineage), with low-passage suspension-culture stewardship.
• Classical screening conventions applied natively — %T/C, ILS_max, QD1-5 schedules, 5-FU controls.
• Hybrid-host expertise, deploying B6D2F1 and CD2F1 testing cohorts alongside DBA/2 propagation.
• Both formats mastered — systemic intraperitoneal and solid "lymphoma-like" tumor geometry.
• Resistance-sublime armory, including P388/ADR and P388/NVB-0.63/2.5 comparators.
• Dissemination-mapping capability, with luciferase variants and milky-spot biology expertise.
• IACUC-compliant, documentation-rich operations delivering audit-ready records throughout the study.

Contact Us

If your lymphoma program needs the most benchmarked tumor system in pharmaceutical history, contact us today to discuss P388 study design, format selection, resistance comparators, and endpoint conventions with our scientific team. Reach out for a confidential consultation and project quotation — Alfa Cytology looks forward to advancing your next preclinical study.

For research use only. Not intended for any clinical use.